AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS)
单位：[1]Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China[2]Peking Union Med Coll Hosp, Dept Oncol, Beijing, Peoples R China[3]Canc Hosp Jilin Prov, Dept Oncol, Changchun, Jilin, Peoples R China[4]Huazhong Univ Sci & Technol, Ctr Canc, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China肿瘤科华中科技大学同济医学院附属同济医院[5]Zhengzhou Univ, Resp Dept Internal Med, Affiliated Canc Hosp, Zhengzhou, Henan, Peoples R China河南省肿瘤医院[6]Chinese Acad Med Sci, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China[7]Peking Union Med Coll, Beijing, Peoples R China[8]Sungkyunkwan Univ, Sch Med, Div Hematol Oncol, Dept Med,Samsung Med Ctr, Seoul, South Korea[9]Sichuan Univ, Dept Thorac Canc, West China Hosp, West China Sch Clin Med, Chengdu, Sichuan, Peoples R China四川大学华西医院[10]Jiangsu Canc Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China[11]Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea[12]Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea[13]Tangdu Hosp, Dept Oncol, Tangdu Comprehens Canc Ctr, Inst Canc, Xian, Shaanxi, Peoples R China[14]AstraZeneca, China Dev Unit, Shanghai, Peoples R China[15]Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China广东省人民医院[16]Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China广东省人民医院
第一作者单位：[1]Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Zhou C.,Wang M.,Cheng Y.,et al.AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS)[J].ANNALS OF ONCOLOGY.2018,29:
APA：
Zhou, C.,Wang, M.,Cheng, Y.,Chen, Y.,Zhao, Y....&Wu, Y-L..(2018).AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS).ANNALS OF ONCOLOGY,29,
MLA：
Zhou, C.,et al."AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS)".ANNALS OF ONCOLOGY 29.(2018)
医学